Recombinant Human CD155/PVR His-tag Avi-tag Protein, CF

Recombinant Human CD155/PVR His-tag Avi-tag Protein, CF Summary

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Data Images

Binding Activity View Larger

When 1 µg/mL of Biotinylated Recombinant Human CD155/PVR His-tag Avi-tag Protein (Catalog # AVI2530) is immobilized onto Streptavidin coated plate (Catalog # CP004) the concentration of Recombinant Human TIGIT Fc Chimera (Catalog # 7898-TGB) binds with an ED₅₀of 0.5-3 ng/mL.

SDS-PAGE View Larger

2 μg/lane of Recombinant Human CD155/PVR Hig-tag Avi-tag (Catalog # AVI2530) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-67 kDa.

Background: CD155/PVR

CD155, also known as PVR (poliovirus receptor), Necl-5 (nectin-like molecule-5) and, in rodents, TAGE4 (tumor-associated glycoprotein E4), is a 70-kDa type I transmembrane glycoprotein in the nectin-related family of adhesion proteins within the immunoglobulin superfamily (1, 2). CD155 binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homotypically (3). Mature human CD155 consists of a 323 amino acid (aa) extracellular domain (ECD) with one N-terminal V-type and two C2-type Ig-like domains, a 24 aa transmembrane segment, and a 50 aa cytoplasmic tail. Within the ECD, human CD155 shares 45% aa sequence identity with mouse and rat CD155, and 52% with human Nectin-2. The V-type domain of CD155 mediates all binding, including to polio virus (1), and alternative splicing within this domain in humans can modulate ligand binding (4). Human CD155 can also be spliced to generate secreted isoforms (5). CD155 is up-regulated on endothelial cells by IFN-gamma and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin (1, 2, 6-9). It is preferentially expressed on Th17 cells compared to Th2 cells (10), and its activation promotes the development of Th1 responses (11). On migrating cells, CD155 is concentrated at the leading edge, where it binds basement membrane Vitronectin, recruits Nectin-3-expressing cells, and cooperates with PDGF and Integrin alpha v beta 3 to promote cell migration (1, 3, 12). Enhanced CD155 expression in tumor cells contributes to loss of contact inhibition and increased migration but also allows tumor cell recognition and killing by DNAM-1 or CD96 expressing NK cells (1, 7, 13). Binding of monocyte DNAM-1 to endothelial cell CD155 promotes transendothelial migration (8). The expression of CD155 on mouse CD8⁺ thymocytes prevents their premature exit from the thymus (14). Within intestinal Peyer's patches, follicular dendritic cell CD155 activates follicular helper T cells via DNAM-1 or CD96 binding (7-9, 15). CD155 also binds the inhibitory ligand TIGIT on NK and some mature T cells, antagonizing DNAM-1 effects (7, 15, 16).

Related Research Areas

• Co-stimulatory and Co-inhibitory Molecules
• Infectious Diseases
• Monocyte Markers
• Nectin and Nectin-like Binding Receptors and Ligands
• Search Immune Checkpoint Targets